Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/04/2005CA2552885A1 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
08/04/2005CA2552784A1 Beta-2-agonists, and their use as medicaments
08/04/2005CA2552781A1 Indol-alanine derivatives as selective s1p4-agonists
08/04/2005CA2552763A1 Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
08/04/2005CA2552759A1 Combination of organic compounds
08/04/2005CA2552754A1 Frequency assisted transdermal agent delivery method and system
08/04/2005CA2552725A1 Treatment of aromatase inhibitor therapy-related osteoporosis
08/04/2005CA2552611A1 Microemulsions for pharmaceutical compositions
08/04/2005CA2552595A1 Directly compressible pharmaceutical composition for the oral admimistration of cci-779
08/04/2005CA2552584A1 Pyrimidyl phosphonate antiviral compounds and methods of use
08/04/2005CA2552362A1 4-aryl piperidines
08/04/2005CA2552359A1 Retinoid-containing preparations
08/04/2005CA2552350A1 Bis-indole pyrroles useful as antimicrobials agents
08/04/2005CA2547963A1 Methods of treating an inflammatory-related disease
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559719A1 Novel macrolide derivatives havaing effect of potentiating antifungal activity
08/03/2005EP1559717A2 Oxabispidine compounds useful in the treatment of cardiac arrythmias
08/03/2005EP1559716A1 Pyrazolonaphthyridine derivative
08/03/2005EP1559715A1 N-[2-chloro-4-(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559709A1 Heterocycle-containing carboxylic acid derivative and drug containing the same
08/03/2005EP1559708A1 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
08/03/2005EP1559707A1 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
08/03/2005EP1559447A1 Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
08/03/2005EP1559446A1 Treating agent for diarrhea-predominant irritable bowel syndrome
08/03/2005EP1559431A1 Pharmaceutical composition for thrombin peptide derivatives
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559427A1 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
08/03/2005EP1559426A1 Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
08/03/2005EP1559425A1 Peroral preparation for prevention of or treatment for atopic dermatitis
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559423A1 Medicinal acidic cannabinoids
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1559421A1 Blood fluidity improving agent
08/03/2005EP1559420A1 Treatment of tinnitus
08/03/2005EP1559419A1 Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
08/03/2005EP1559398A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins
08/03/2005EP1559374A1 Cyanine dyes
08/03/2005EP1559321A1 Mixed compositions for controlling parasitic insects
08/03/2005EP1558630A2 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use
08/03/2005EP1558620A1 Ruthenium anticancer complexes
08/03/2005EP1558616A2 Meso-substituted porphyrins
08/03/2005EP1558615A1 Purine compounds and use thereof as cannabinoid receptor ligands
08/03/2005EP1558614A1 Pyridopyrrolizine and pyridoindolizine derivatives
08/03/2005EP1558611A2 Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
08/03/2005EP1558609A2 Kinase inhibitors
08/03/2005EP1558606A2 Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
08/03/2005EP1558604A1 Quaternary ammonium compounds and their use as antimuscarinic agents
08/03/2005EP1558601A1 Selected cgrp antagonists, method for production and use thereof as medicament
08/03/2005EP1558599A2 Heteroarylpiperidine modulators of chemokine receptor activity
08/03/2005EP1558591A2 Modulation of anxiety through blockade of anandamide hydrolysis
08/03/2005EP1558588A2 Compounds, compositions, and methods
08/03/2005EP1558586A2 Inhibitors of akt activity
08/03/2005EP1558585A1 Neurologically-active compounds
08/03/2005EP1558578A1 Novel alkyne compounds having an mch antagonistic effect and medicaments containing these compounds
08/03/2005EP1558577A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
08/03/2005EP1558565A2 Halogenated selective androgen receptor modulators and methods of use thereof
08/03/2005EP1558562A1 Cationic cardiolipin analogs and use thereof
08/03/2005EP1558559A1 Manufacturing process for no-donating compounds such as no-donating diclofenac
08/03/2005EP1558341A2 Transcription factor modulating compounds and methods of use thereof
08/03/2005EP1558290A2 Heat pasteurized liquids containing glucosamine
08/03/2005EP1558289A1 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
08/03/2005EP1558288A1 Gastric acid secretion inhibiting composition
08/03/2005EP1558282A2 Anti-cancer and anti-infectious disease compositions and methods for using same
08/03/2005EP1558272A1 Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
08/03/2005EP1558271A2 Compositions that treat or inhibit pathological conditions associated with inflammatory response
08/03/2005EP1558270A1 Dietary supplement comprising parthenolide
08/03/2005EP1558268A2 Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
08/03/2005EP1558267A1 Use of fosinopril to reduce cardiovascular events in dialysis patients
08/03/2005EP1558266A2 Treatment for reactive arthritis or bursitis
08/03/2005EP1558265A1 Cardiovascular protection using anti-aldosteronic progestins
08/03/2005EP1558264A2 Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases
08/03/2005EP1558263A1 Prolonged release pharmaceutical composition
08/03/2005EP1558262A1 Water-soluble meloxicam granulates
08/03/2005EP1558261A2 Quinazolinone compositions for regulation of gene expression related to pathological processes
08/03/2005EP1558260A2 Quinazolinone compounds as calcilytics
08/03/2005EP1558259A2 Il-8 receptor antagonists
08/03/2005EP1558258A1 Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
08/03/2005EP1558257A1 Dosage form that is safeguarded from abuse
08/03/2005EP1558256A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
08/03/2005EP1558255A2 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
08/03/2005EP1558254A2 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye, compositions resulting therefrom
08/03/2005EP1558253A2 Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
08/03/2005EP1558252A2 Substituted furo 2,3-b] pyridine derivatives
08/03/2005EP1558251A1 Method of treatment of psychological conditions by administration of nerve growth factor
08/03/2005EP1558250A1 Gamma-aminoamide modulators of chemokine receptor activity
08/03/2005EP1558249A1 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma
08/03/2005EP1558248A1 Derivatives of [6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide as anti-inflammatory agents
08/03/2005EP1558247A1 Benzimidazole derivatives
08/03/2005EP1558246A1 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
08/03/2005EP1558245A2 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
08/03/2005EP1558244A2 Novel nutraceutical compositions comprising epigallocatechin gallate
08/03/2005EP1558243A2 Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
08/03/2005EP1558242A1 Combination comprising docetaxel and a cdk inhibitor
08/03/2005EP1558241A2 Pharmaceutical compositions and methods of using taxane derivatives
08/03/2005EP1558240A2 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia
08/03/2005EP1558239A1 Combination comprising a cdk inhibitor and cisplatin
08/03/2005EP1558238A2 Beta-hydroxyphenylaldylamines and their use for treating glaucoma
08/03/2005EP1558237A2 Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid
08/03/2005EP1558236A1 Lysine mixture and apparatus and method for administering lysine
1 ... 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 4611 4612 4613 ... 7860